STOCK TITAN

Nephros Inc - NEPH STOCK NEWS

Welcome to our dedicated news page for Nephros (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nephros's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nephros's position in the market.

Rhea-AI Summary
Nephros, Inc. reports strong financial results for the fourth quarter and fiscal year ended December 31, 2023, with net revenue reaching $14.2 million for the year. The company saw a 43% increase in net revenue compared to the previous year, along with significant improvements in adjusted EBITDA. Nephros attributes its success to streamlined operations, a focus on filtration solutions, and strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.6%
Tags
-
Rhea-AI Summary
Nephros, Inc. (NEPH) to release Q4 and fiscal year financial results on March 7, 2024, followed by a conference call. The company offers filtration solutions for medical and commercial markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
-
Rhea-AI Summary
Nephros, Inc. (Nasdaq: NEPH) announces third-quarter net revenue of $3.7 million, a 55% increase over 2022, with net loss from continuing operations narrowing 85% to $0.2 million. The company also reports $1.1 million in positive year-to-date net cash flows from operating activities. The financial performance highlights include third-quarter adjusted EBITDA positive $11,000, compared to negative $304,000 in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
Rhea-AI Summary
Nephros, Inc. appoints Judy Krandel as Chief Financial Officer. She brings over 20 years of experience in financial leadership and strategic planning. The company's retiring CFO expresses confidence in Krandel's ability to lead. Krandel joins Nephros at a time of positive cash flows and growing revenue momentum. She will receive a 10-year stock option grant to purchase 122,524 shares of the company's common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
management
-
Rhea-AI Summary
Nephros, Inc. will file its Q3 financial results on November 8, 2023, and host a conference call. Dial-in details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
-
Rhea-AI Summary
Nephros, Inc. to present at LD Micro Main Event XV
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
conferences
Rhea-AI Summary
Nephros reports Q2 net revenue of $3.5M, a 24% increase YoY; YTD revenue up 45%; maintains positive cash flow. Gross margins improve to 59%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.86%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
Nephros Inc

Nasdaq:NEPH

NEPH Rankings

NEPH Stock Data

21.09M
5.62M
11.96%
40.29%
0.02%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
South Orange

About NEPH

nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil